Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
NCT06025110 · ITB-Med LLC · PHASE2 · terminated · last registry update 2025-08-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.” | – | Registry record, ITB-Med LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-28Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Siplizumab (NCT05574335)
- 2026-07-28Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Siplizumab (NCT05574335)
- 2026-07-17Also stopped (terminated): ITB-Med LLC, TCD601 (NCT06453668)
- 2026-07-13Also stopped (terminated): ITB-Med LLC, TCD601 (NCT04803058)
- 2026-06-10Also stopped (terminated): Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2026-03-12Results posted on the registry: ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT06365437)
- 2026-03-12Also stopped (terminated): ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT06365437)
- 2026-02-27Results posted on the registry: Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2025-02-27Results posted on the registry: ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT04311632)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision